CN109260460A - It is a kind of for preventing and treating the pharmaceutical composition of eye illness and rhinitis - Google Patents
It is a kind of for preventing and treating the pharmaceutical composition of eye illness and rhinitis Download PDFInfo
- Publication number
- CN109260460A CN109260460A CN201811340720.7A CN201811340720A CN109260460A CN 109260460 A CN109260460 A CN 109260460A CN 201811340720 A CN201811340720 A CN 201811340720A CN 109260460 A CN109260460 A CN 109260460A
- Authority
- CN
- China
- Prior art keywords
- collagen peptide
- rhinitis
- pharmaceutical composition
- eye illness
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
The embodiment of the invention discloses a kind of for preventing and treating the pharmaceutical composition of eye illness and rhinitis; component including following weight percentage: collagen peptide stoste 85-99.8%, shark chondroitin 0.1-15%, taurine 0.1-10%; the collagen peptide stoste is the aqueous solution of collagen peptide; wherein, the mass fraction of collagen peptide is 30-70%.The embodiment of the invention also discloses a kind of for preventing and treating the preparation method and application of the pharmaceutical composition of eye illness and rhinitis.Synergistic function is played between each component of the present invention, eye is applied to be absorbed by eyes, enter nasolacrimal duct and nasal cavity with tear general pipeline in succession, it is covered with reticular structure with upper bit and is directly absorbed by schneiderian membrance, had and kill unwanted cells, improves microcirculation, replace restoring ocular, nose hurt and the cell decayed, injury tissue is promoted to restore the effect of body health, which can effectively prevent eye illness and rhinitis, have the advantages that good stability, nonirritant, preservative free and curative for effect.
Description
Technical field
The present invention relates to technical field of pharmaceuticals, and in particular to a kind of for preventing and treating the pharmaceutical composition of eye illness and rhinitis.
Background technique
Collagen and shark chondroitin enable eyes light transmission, and cornea, retina keep transparent, and cornea is eye
One of important feature in eyeball, collagen fabric presentation contained therein is regularly arranged, and such structure can not only allow light to penetrate,
Also because of the special arrangement mode of such collagen fabric, cornea presents transparent.
With advancing age, the missing of collagen, the middle-aged and the old be easy to generate maculopathy, glaucoma, it is white in
The diseases such as barrier, presbyopia.Traditional spongarion, eyedrops are difficult to solve to lack because of eye collagen, and cell damage is decayed and made
At eye disease insalubrity is used for a long time so that the above eye illness is difficult to restore, and because containing preservative more.
The nose structure of people is extremely complex, is influenced by environmental pollution and weather etc., and the bronchia mucosal of many people is impaired tight
Weight, especially sand and dust are big, are air-dried, seriously polluted area, and the crowd for suffering from allergic rhinitis increases increasingly.Although there are many at present
The drug of rhinitis is treated, but uncertain therapeutic efficacy is cut.Simultaneously because the drug of general treatment rhinitis is difficult to arrive above nasal cavity, to treatment
Bring many difficulties.
Collagen is a kind of extracellular protein, it is to twist into spiral fibrous proteins knot by 3 α polypeptide chains
Structure, molecular structure is sufficiently stable, and relative molecular weight is unfavorable for human body and directly absorbs in 30KDa or more.Ammonia in collagen
Potential many biologically active amino acid sequences in base acid sequence, but can not be showed since its activated centre is embedded
Its due bioactivity, therefore make the exposure of its activated centre have a variety of biologies living by digesting obtained collagen peptide
Property.Studies have shown that the primary product collagen peptide of collagen protein enzymolysis, has protection gastric mucosa, antiulcer, inhibits on blood pressure
It rises, the physiological functions such as promoting bone growing, skin collagen metabolism have huge development prospect in field of medicaments.
Summary of the invention
Being designed to provide for the embodiment of the present invention is a kind of for preventing and treating the pharmaceutical composition of eye illness and rhinitis, to solve
The problem of existing drug administration is difficult, uncertain therapeutic efficacy is cut.
To achieve the above object, the first aspect of the embodiment of the present invention provides a kind of for preventing and treating the medicine of eye illness and rhinitis
Compositions, described pharmaceutical composition include the component of following weight percentage: collagen peptide stoste 85-99.8%, shark
Fish chondroitin 0.1-15%, taurine 0.1-10%, the collagen peptide stoste are the aqueous solution of collagen peptide, wherein
The mass fraction of collagen peptide is 30-70%.
Collagen peptide stoste can be commercially available by commercial sources, or in manners known to the person skilled in the art
It is prepared, in a preferred embodiment, selects papain hydrolysis collagen, take a certain amount of collagen,
The papain that mass percent is 1% is added, digests 8h under conditions of 55 DEG C, pH are 6.5, then 90 DEG C of water-bath enzyme deactivations
10min takes supernatant, evaporation adjustment moisture content, it is 30-70% that mass fraction, which can be obtained, through high density strainer, membrane filtration
Collagen peptide stoste.
Further, described pharmaceutical composition includes the component of following weight percentage: collagen peptide stoste 88-
99%, shark chondroitin 1-7%, taurine 1-5%, the collagen peptide stoste are the aqueous solution of collagen peptide, wherein
The mass fraction of collagen peptide is 32-70%.
Further, described pharmaceutical composition includes the component of following weight percentage: collagen peptide stoste 92-
97%, shark chondroitin 2-5%, taurine 1-3%, the collagen peptide stoste are the aqueous solution of collagen peptide, wherein
The mass fraction of collagen peptide is 40-70%.
Further, the collagen peptide is animal sources collagen peptide or human-like collagen peptide.
The second aspect of the embodiment of the present invention provides a kind of above-mentioned pharmaceutical composition for being used to prevent and treat eye illness and rhinitis
Preparation method, under aseptic conditions, shark chondroitin and taurine are added in collagen peptide stoste, stirs,
Obtain transparence soft paste, packing.
The third aspect of the embodiment of the present invention provides above-mentioned pharmaceutical composition in preparation for preventing and treating eye illness and rhinitis
Drug in application.
Further, the eye illness includes maculopathy, glaucoma, cataract, presbyopia.
Further, the rhinitis is allergic rhinitis.
Shark chondroitin also known as sulfuric acid shark chondroitin are a kind of acid mucopolysaccharide, be important composition in ocular tissue it
One, have the function of promoting cornea water metabolism, improve microcirculation, protect cornea and promote cornea tissue injury repair, simultaneously
Also layer protecting film can be formed in anterior corneal surface, prevent moisture from distributing, visual fatigue and dry eye condition is effectively relieved；Taurine removes can
Outside antibacterial anti-inflammatory, a variety of physiological activities are also participated in ocular tissue, are boosted metabolism, improve visual fatigue.
The embodiment of the present invention has the advantages that
The pharmaceutical composition of the embodiment of the present invention is using collagen peptide, shark chondroitin, taurine as raw material, between component
Synergistic function is played, eye is applied and generates tears, enter nasolacrimal duct with tear general pipeline in succession and directly absorbed by schneiderian membrance, had
Unwanted cells are killed, microcirculation is improved, replace the cell that eye, nose are damaged and decay, promotes injury tissue reparation, restores machine
The effect of body health, clinical research shows that the pharmaceutical composition can effectively prevent various eye diseases, such as maculopathy, green light
Eye, cataract, presbyopia and allergic rhinitis etc., with stability is good, nonirritant, preservative free and curative for effect excellent
Point.
Specific embodiment
Present invention will be further explained by specific examples below, it should be understood, however, that, these embodiments are only
It is used, is but should not be understood as present invention is limited in any form for specifically describing in more detail.
This part carries out general description to the material and test method that arrive used in present invention test.Although being
It realizes many materials used in the object of the invention and operating method is it is known in the art that still the present invention still uses up herein
It may detailed description.It will be apparent to those skilled in the art that within a context, if not specified, material therefor of the present invention and behaviour
It is well known in the art as method.
Embodiment 1
The pharmaceutical composition for being used to prevent and treat eye illness and rhinitis of the present embodiment, is prepared by the following preparation method: sterile item
Under part, shark chondroitin 8g and taurine 7g is added in collagen peptide stoste 85g, stirs, obtains transparence
Soft paste, packing, wherein collagen peptide stoste is the aqueous solution of collagen peptide, the mass fraction of collagen peptide
It is 45%.
Embodiment 2
The pharmaceutical composition for being used to prevent and treat eye illness and rhinitis of the present embodiment, is prepared by the following preparation method: sterile item
Under part, shark chondroitin 6g and taurine 4g is added in collagen peptide stoste 90g, stirs, obtains transparence
Soft paste, packing, wherein collagen peptide stoste is the aqueous solution of collagen peptide, the mass fraction of collagen peptide
It is 50%.
Embodiment 3
The pharmaceutical composition for being used to prevent and treat eye illness and rhinitis of the present embodiment, is prepared by the following preparation method: sterile item
Under part, shark chondroitin 5g and taurine 4g is added in collagen peptide stoste 91g, stirs, obtains transparence
Soft paste, packing, wherein collagen peptide stoste is the aqueous solution of collagen peptide, the mass fraction of collagen peptide
It is 50%.
Embodiment 4
The pharmaceutical composition for being used to prevent and treat eye illness and rhinitis of the present embodiment, is prepared by the following preparation method: sterile item
Under part, shark chondroitin 4g and taurine 3g is added in collagen peptide stoste 93g, stirs, obtains transparence
Soft paste, packing, wherein collagen peptide stoste is the aqueous solution of collagen peptide, the mass fraction of collagen peptide
It is 50%.
Embodiment 5
The pharmaceutical composition for being used to prevent and treat eye illness and rhinitis of the present embodiment, is prepared by the following preparation method: sterile item
Under part, shark chondroitin 3g and taurine 2g is added in collagen peptide stoste 94g, stirs, obtains transparence
Soft paste, packing, wherein collagen peptide stoste is the aqueous solution of collagen peptide, the mass fraction of collagen peptide
It is 50%.
Embodiment 6
The pharmaceutical composition for being used to prevent and treat eye illness and rhinitis of the present embodiment, is prepared by the following preparation method: sterile item
Under part, shark chondroitin 3g and taurine 8g is added in collagen peptide stoste 95g, stirs, obtains transparence
Soft paste, packing, wherein collagen peptide stoste is the aqueous solution of collagen peptide, the mass fraction of collagen peptide
It is 50%.
Comparative example 1
The difference of the pharmaceutical composition and embodiment 1 for preventing and treating eye illness and rhinitis of this comparative example is only that, is not included
Shark chondroitin and taurine.
Comparative example 2
The difference of the pharmaceutical composition and embodiment 1 for preventing and treating eye illness and rhinitis of this comparative example is only that, using etc.
The collagen of amount replaces collagen peptide.
Comparative example 3
The difference of the pharmaceutical composition and embodiment 1 for preventing and treating eye illness and rhinitis of this comparative example is only that, using etc.
The chitosan of amount replaces taurine.
Test case
1 sense organ and physical and chemical index test
The appearance of pharmaceutical composition made from 1-6 of the embodiment of the present invention, pH value, heat-resisting and cold-resistant stability are surveyed
Examination, the results are shown in Table 1.
Table 1
| Test item | Test result |
| Appearance | Light yellow ointment, lotion uniform and smooth |
| PH value | 6.0-7.0 |
| Heat-resistant stability | 40 ± 1 DEG C keep for 24 hours, restore room temperature after with test before indifference |
| Cold-resistant stability | 3 ± 1 DEG C keep for 24 hours, restore room temperature after with test before indifference |
2 stability tests
The pharmaceutical composition for taking 1-6 of the embodiment of the present invention, temperature be (25 ± 2) DEG C, relative humidity (RH) be (60 ±
10) it is placed 12 months under conditions of %, respectively at the 0th, 3,6,9,12 the end of month sampling, according to as defined in " Chinese Pharmacopoeia " 2005 editions
Eye ointments emphasis detection project (appearance character, pH, hygiene) is detected, and the results are shown in Table 2.
Table 2
The result shows that: compared with 0 month data, the 3rd, 6,9, December, indices were showed no significant change.
The experiment of 3 eye irritations
Health, new zealand rabbit 18 without eye illness are taken, is randomly divided into six groups, every group of 3 rabbits totally 6 eyes.Every group of rabbit
Successive administration 28d, left eye give the pharmaceutical composition of 1-6 of the embodiment of the present invention respectively, are often only given 100mg, right eye point every time
The physiological saline that mass concentration is 0.9% is not given, is often only given 1-2 drop every time.Right and left eyes are per average daily administration 6 times, in each
Before administration, the 8th, 15,22 day about 1h and the 28th day the 1st, 2,4,24,48,72h after the last administration after the last administration, with fluorescence uniformly dyeing
The local reaction situation of whole lagophthalmos eyeballs is observed in color inspection and slit lamp examination.
It scores with reference to the eye irritant tests of " pharmacology test ", Zhang Yuanpei chief editor, People's Health Publisher, 1996 records,
The stimulate the reaction score value of the cornea of each animal of each observing time, iris and conjunctiva is added to obtain total mark, by one group
Integral, to get last score value, then can determine whether its stimulation degree by eye irritation evaluation criterion divided by number of animals.28d is observed,
Experimental result is shown in Table 3.
Table 3
| Group | Integral | Stimulation degree |
| Embodiment 1 | 0 | It is nonirritant |
| Embodiment 2 | 0 | It is nonirritant |
| Embodiment 3 | 0 | It is nonirritant |
| Embodiment 4 | 0 | It is nonirritant |
| Embodiment 5 | 0 | It is nonirritant |
| Embodiment 6 | 0 | It is nonirritant |
The result shows that: all rabbit or so cornea, iris and conjunctiva are showed no apparent irritation, show of the invention real
The pharmaceutical composition for applying example is nonirritant to eye.
4 zooperies
The foundation of ultraviolet light cataract rat model
By 6 week old, 35 SD rats (half male and half female) that weight is 180-220g, every intraperitoneal injection 100g/L hydration
Chloral 0.6-0.7mL is anaesthetized, and is placed under 300nm ultraviolet radiator, and it is double to irradiate SD rat respectively for fixed relative position, distance
(after Tropicamide ocular fluid and neophryn ocular fluid routine expansion pupil, 15min/ times daily, accumulated illumination is daily 9KJ/m to eye2, continuously
7d).2d starts slight phacoscotasmus occur after radiation, and 7d can form typical cortical cataract, modeling success.
By modeling success rat, be randomly divided into 7 groups, every group of 5 rabbits totally 10 eyes, respectively model group, experiment 1-3 group,
1-3 group is compareed, wherein model group gives physiological saline eye drops, and experimental group 1-3 group gives the medicine that embodiment 1,3,5 obtains respectively
Compositions, control group 1-3 group give the obtained pharmaceutical composition of comparative example 1-3 respectively.Each group is administered daily 3 times, is given every time
Pharmaceutical quantities be 50mg/ eye, successive administration 4 weeks.The metamorphosis of slit lamp microscope observation SD rat lens is used daily.
Lens opacity degree is divided into following 4 grades: 1 grade of crystalline lens is transparent；2 grades of anterior capsules and periphery are muddy；3 grades of cracks
The visible frontal cortex of lamp is muddy；4 grades of cortex are muddy obvious, and naked eyes are i.e. visible.
After being administered 4 weeks, through examination with slitlamp microscope, the lenticular metamorphosis of each group the results are shown in Table 4.
Table 4
| Group | 1 grade | 2 grades | 3 grades | 4 grades |
| Model group | 0/10 | 0/10 | 2/10 | 8/10 |
| Test 1 group | 8/10 | 2/10 | 0/10 | 0/10 |
| Test 2 groups | 9/10 | 1/10 | 0/10 | 0/10 |
| Test 3 groups | 8/10 | 1/10 | 1/10 | 0/10 |
| Compare 1 group | 0/10 | 5/10 | 3/10 | 2/10 |
| Compare 2 groups | 0/10 | 2/10 | 4/10 | 4/10 |
| Compare 3 groups | 0/10 | 3/10 | 5/10 | 2/10 |
The result shows that: compared to the pharmaceutical composition of comparative example 1-3, the pharmaceutical composition of the embodiment of the present invention is for white interior
Barrier has significant therapeutic effect.
5 clinical tests
5.1 general information
It selects in June, 2010 in August, -2016 to receive this trial drug composition and is diagnosed as Dry macular lesion patient 35
Example (wherein have 8 patients while suffering from allergic rhinitis), glaucoma patient 42 (wherein have 6 patients while suffering from allergy
Property rhinitis), cataract patient 55 (wherein have 15 patients while suffering from allergic rhinitis), patients with presbyopia 48 (wherein
Have 12 patients while suffering from allergic rhinitis) as research object.All patients are divided into treatment 1-2 by random digits table
Group and control group, every group equal 60.Treat 1 group of male 29, women 31；Age 52-75 years old, average (65.7 ± 8.5) year；
The course of disease 4-12 months, average (6.8 ± 2.7) a month.Treat 2 groups of males 36, women 24；It is age 55-76 years old, average
(69.6 ± 6.5) year；The course of disease 3-12 months, average (6.2 ± 3.3) a month.Control group male 33, women 27；Age 55-
78 years old, average (67.2 ± 5.8) year；The course of disease 5-13 months, average (6.9 ± 2.5) a month.Every group of patient is in gender, age, disease
The basic documents such as feelings type compare, and difference is not statistically significant (P > 0.05), are comparable.All patients endorsed
Informed consent form.
5.2 evaluation criterion
Cure: clinical symptoms improve substantially after the treatment or all disappear；
Effective: clinical symptoms are improved after the treatment；
Invalid: symptom is not apparent from mitigation or exacerbation.
5.3 treatment method
The pharmaceutical composition of Examples 1 and 2: being coated in the inside of every group of patient's lower eyelid by treatment 1-2 group respectively, and daily 3
It is secondary.
Control group: by ZHENSHIMING DIYANYE drop in patient's eyelid, a 1-2 drop, 3 times a day.
5.4 result
It was treated by 30 days, the clinical therapeutic efficacy comparing result of two groups of eye illnesses is shown in Table 5.
Table 5
| Group | Number of cases | It cures | Effectively | In vain | Total effective rate/% |
| Treat 1 group | 60 | 20 | 24 | 16 | 73.3 |
| Treat 2 groups | 60 | 22 | 23 | 15 | 75 |
| Control group | 60 | 4 | 18 | 38 | 36.7 |
The result shows that: the pharmaceutical composition of the embodiment of the present invention is for including maculopathy, glaucoma, cataract, presbyopic
The eye illness of eye has good therapeutic effect.
It was treated by 30 days, the clinical therapeutic efficacy comparing result of two groups of rhinitis is shown in Table 6.
Table 6
| Group | Number of cases | It cures | Effectively | In vain | Total effective rate/% |
| Treat 1 group | 14 | 6 | 5 | 3 | 78.6 |
| Treat 2 groups | 14 | 5 | 5 | 4 | 71.4 |
| Control group | 13 | 3 | 2 | 8 | 38.5 |
The result shows that: the pharmaceutical composition of the embodiment of the present invention has good therapeutic effect for allergic rhinitis.
Although above having used general explanation and specific embodiment, the present invention is described in detail, at this
On the basis of invention, it can be made some modifications or improvements, this will be apparent to those skilled in the art.Therefore,
These modifications or improvements without departing from theon the basis of the spirit of the present invention are fallen within the scope of the claimed invention.
Claims (8)
1. a kind of for preventing and treating the pharmaceutical composition of eye illness and rhinitis, which is characterized in that described pharmaceutical composition includes following heavy
Measure the component of percentage composition: collagen peptide stoste 85-99.8%, shark chondroitin 0.1-15%, taurine 0.1-10%, institute
State the aqueous solution that collagen peptide stoste is collagen peptide, wherein the mass fraction of collagen peptide is 30-70%.
2. according to claim 1 for preventing and treating the pharmaceutical composition of eye illness and rhinitis, which is characterized in that the medicine group
Close the component that object includes following weight percentage: collagen peptide stoste 88-99%, shark chondroitin 1-7%, taurine 1-
5%, the collagen peptide stoste is the aqueous solution of collagen peptide, wherein the mass fraction of collagen peptide is 32-
70%.
3. according to claim 1 for preventing and treating the pharmaceutical composition of eye illness and rhinitis, which is characterized in that the medicine group
Close the component that object includes following weight percentage: collagen peptide stoste 92-97%, shark chondroitin 2-5%, taurine 1-
3%, the collagen peptide stoste is the aqueous solution of collagen peptide, wherein the mass fraction of collagen peptide is 40-
70%.
4. according to claim 1 for preventing and treating the pharmaceutical composition of eye illness and rhinitis, which is characterized in that the collagen egg
White peptide is animal sources collagen peptide or human-like collagen peptide.
5. a kind of described in claim 1 for preventing and treating the preparation method of the pharmaceutical composition of eye illness and rhinitis, which is characterized in that
Under aseptic condition, shark chondroitin and taurine are added in collagen peptide stoste, stirs, it is soft to obtain transparence
Lotion, packing.
6. pharmaceutical composition described in claim 1 is preparing the application in the drug for preventing and treating eye illness and rhinitis.
7. pharmaceutical composition according to claim 6 is preparing the application in the drug for preventing and treating eye illness and rhinitis,
It is characterized in that, the eye illness includes maculopathy, glaucoma, cataract, presbyopia.
8. pharmaceutical composition according to claim 6 is preparing the application in the drug for preventing and treating eye illness and rhinitis,
It is characterized in that, the rhinitis is allergic rhinitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811340720.7A CN109260460A (en) | 2018-11-12 | 2018-11-12 | It is a kind of for preventing and treating the pharmaceutical composition of eye illness and rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811340720.7A CN109260460A (en) | 2018-11-12 | 2018-11-12 | It is a kind of for preventing and treating the pharmaceutical composition of eye illness and rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109260460A true CN109260460A (en) | 2019-01-25 |
Family
ID=65192278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811340720.7A Pending CN109260460A (en) | 2018-11-12 | 2018-11-12 | It is a kind of for preventing and treating the pharmaceutical composition of eye illness and rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109260460A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116726142A (en) * | 2023-06-12 | 2023-09-12 | 湖北健肽生物科技有限公司 | Collagen tripeptide with eye protection function |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07223966A (en) * | 1994-02-08 | 1995-08-22 | Seiko Epson Corp | Artificial lacrima for ophthalmology |
| CN101129698A (en) * | 2007-09-18 | 2008-02-27 | 陈苏莉 | Eye drops containing turmeric extractive and preparation method thereof |
| CN101455628A (en) * | 2007-12-14 | 2009-06-17 | 杨文龙 | Gel composition for eyes and preparation method thereof |
| CN101543509A (en) * | 2008-03-28 | 2009-09-30 | 刘继东 | Ophthalmic gel containing chondroitin sulfate and method for preparing same |
-
2018
- 2018-11-12 CN CN201811340720.7A patent/CN109260460A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07223966A (en) * | 1994-02-08 | 1995-08-22 | Seiko Epson Corp | Artificial lacrima for ophthalmology |
| CN101129698A (en) * | 2007-09-18 | 2008-02-27 | 陈苏莉 | Eye drops containing turmeric extractive and preparation method thereof |
| CN101455628A (en) * | 2007-12-14 | 2009-06-17 | 杨文龙 | Gel composition for eyes and preparation method thereof |
| CN101543509A (en) * | 2008-03-28 | 2009-09-30 | 刘继东 | Ophthalmic gel containing chondroitin sulfate and method for preparing same |
Non-Patent Citations (1)
| Title |
|---|
| 闵瑞: "微波辅助酶解提取硫酸软骨素下脚料中胶原蛋白肽的工艺研究", 《粮食与食品工业》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116726142A (en) * | 2023-06-12 | 2023-09-12 | 湖北健肽生物科技有限公司 | Collagen tripeptide with eye protection function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220306704A1 (en) | Neurotoxins for use in inhibiting cgrp | |
| CN102145126B (en) | Pharmaceutical composition for treating xerophthalmia | |
| SK140594A3 (en) | Manufacture and application of non-immunogenic enzymatic pharmaceutical agents isolated from antarctic krill | |
| CN101648018A (en) | Medicinal composition for treating ophthalmic inflammation and application thereof | |
| Spadea et al. | Recovery of corneal sensitivity after collagen crosslinking with and without epithelial debridement in eyes with keratoconus | |
| CN105106318B (en) | A kind of Chinese medicine composition and preparation method thereof for treating xerophthalmia | |
| CN104940994B (en) | A kind of artificial schneiderian membrane and application thereof | |
| CN109260460A (en) | It is a kind of for preventing and treating the pharmaceutical composition of eye illness and rhinitis | |
| RU2652581C1 (en) | Method of corneoconjunctival xerosis treatment | |
| CN105214071A (en) | A kind of size variance eye drop and preparation method thereof | |
| CN101366726A (en) | Medicament composition for treating skin diseases | |
| CN108379558A (en) | Application of the interleukin 22 in the drug for preparing treatment persistent corneal epithelial defects | |
| CN105963319A (en) | Saturated hydrogen saline water washing liquor and preparation method and application thereof | |
| RU2733392C1 (en) | Combined ophthalmic agent | |
| RU2716429C1 (en) | Method of treating recurrent erosion of corneas of various origins | |
| CN113262235B (en) | New application of new agaro-oligosaccharide in treating ophthalmic diseases | |
| Schrader | Traditional cataract treatment and the healers perspective: Dialogue with western science and technology in Nigeria, West Africa | |
| CN103505578B (en) | The bark of eucommia is mended day plain sheet in the application of the few essence of the male sex, weak essence, semen liquefaction shape | |
| CN109260458A (en) | Collagen Implant is preparing the purposes in operation for glaucoma auxiliary reconstruction | |
| Ziad et al. | Evaluation of Lycium Shawii Schult & Roem Eye Drops as a Novel Treatment for Old Corneal Scars in Rabbits | |
| Ion et al. | Treatment of bullous keratopathy in the dog. | |
| RU2391950C1 (en) | Dry eye syndrom and eye forepart superficial injures treatment method | |
| Akhand et al. | A comparative study on effect of bilvadi yogaashchyotana and haritaki vidalaka in the management of vataja abhishyanda wsr to simple allergic conjunctivitis. | |
| Patel et al. | Clinical profile of toxic keratoconjunctivitis after ocular trauma with insect | |
| CN105214092B (en) | RHuIL-1Ra and combinations thereof and medicinal usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |